pcsk9 loss-of-function mutations
Post on 31-Dec-2015
92 Views
Preview:
DESCRIPTION
PCSK9 Loss-of-function Mutations. PCSK9-Mediated Degradation of LDL-R. Evolution of Therapeutic Monoclonal Antibodies. Effect of PCSK9 Inhibitors on LDL-C in Heterozygous FH. DESCARTES % Change in LDL-C From Baseline at Week 52 in Patients With Hypercholesterolemia. - PowerPoint PPT Presentation
TRANSCRIPT
PCSK9 Loss-of-function Mutations
PCSK9-Mediated Degradation of LDL-R
Evolution of Therapeutic Monoclonal Antibodies
Effect of PCSK9 Inhibitors on LDL-C in Heterozygous FH
DESCARTES% Change in LDL-C From Baseline at Week 52 in Patients With
Hypercholesterolemia
GAUSS-1% Change in LDL-C From Baseline at Week 12 in Statin-Intolerant Patients
Effect of PCSK9 Monoclonal Antibodies on ApoB and Lp(a)
Role of apoB
How Low Is Too Low?
PCSK9 CV Outcomes Trials
TESLATrial Evaluating PCSK9 Antibody in Homozygous FH
Abbreviations
Abbreviations (cont)
References
References (cont)
References (cont)
top related